596results about How to "Inhibition of differentiation" patented technology

The invention relates to methods and compositions for the differentiation of stromal cells from adipose tissue into hematopoietic supporting stromal cells and myocytes of both the skeletal and smooth muscle type. The cells produced by the methods are useful in providing a source of fully differentiated and functional cells for research, transplantation and development of tissue engineering products for the treatment of human diseases and traumatic tissue injury repair.

A polypeptide which contains the amino acid sequence described in SEQ ID NO: 1 in the Sequence Listing encoded by a gene originating in human being. Because of serving as a chemical efficacious in the supression of the proliferation and defferentiation of undifferentiated blood cells. this polypeptide is expected to be usable in medicines and medical supplies.

The invention involves methods of inhibiting the cancer cell cycle to make cancer cells more susceptible to chemotherapeutic agents. In particular, inhibition of CDK4 and / or CDK6 inhibits cell cycle progression in cancer cells. When combined with chemotherapy such cell cycle inhibition can effectively treat even aggressive cancer types that are drug-resistant and intractable to most chemotherapies.

Methods for preventing or treating an IgE-mediated allergic disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.

The active hypolipemic components in 40 Chinese-medicinal materials and their relative medicines are disclosed. Said active components can suppress the activity of fatty acid synthetase and the differentiation from profat cells to fat cells and activate the activity of acyl-CoA synthetase. Said medicines feature high effect and low toxic by-effect.

Provided are ex vivo and in vivo methods of expanding renewable stem cells using modulators of PI 3-kinase activity, expanded populations of renewable stem cells, and uses thereof.

The invention provides compositions comprising an effective amount of an agent that inhibits a BET protein (e.g., Brd2, Brd3, Brd4), and methods of using such compositions for treating or preventing metabolic syndrome, obesity, type II diabetes, insulin resistance, and related disorders characterized by undesirable alterations in metabolism or fat accumulation.

The present invention relates to methods of using granulocyte colony stimulating factor (G-CSF) polypeptide, alone and in conjunction with stromal cell derived factor (SDF-1) polypeptide, to increase the mobilization of c-Kit+ stem cells in the blood, bone marrow, tissue, heart or other organs for the subsequent production of embryoid body-like cell clusters. These embryoid body-like cell clusters can be used for cell replacement therapy, for the treatment of cardiac myopathy and other diseases and disorders, and for screening agents that drive or inhibit differentiation and proliferation.

The present invention provides the prophylaxis and treatment of bone and joint diseases by regulating the expression or activity of calmodulin, the prophylaxis and treatment of bone and joint diseases by regulating the expression or activity of asporin, and a diagnostic method for genetic susceptibility to bone and joint diseases by detecting polymorphisms in the CALM1 gene and / or the asporin gene, and the like.

The invention provides methods for the treatment or prevention of obesity. The invention also provides screening methods for determining whether a compound is useful for the treatment or prevention of obesity.

Ex-vivo methods of expanding hematopoietic stem cells of hematopoietic mononuclear cells that comprise a major fraction of hematopoietic committed cells and a minor fraction of hematopoietic stem and progenitor cells, expanded populations of hematopoietic stem cells obtained thereby and their uses are disclosed.

Amino acids constituting a physiologically active molecule human delta 2; a gene arrangement thereof; and an antibody thereto. The human delta 2 molecule, at least the amino acid sequence described in SEQ ID NO: 1 of the sequence listing, functions as a chemical useful for proliferation of undifferentiated blood cells and inhibition of differentiation, and hence can be utilized as pharmaceuticals and medical supplies.

The invention discloses a low compression ratio 690MPa grade extra thick steel plate and a production method thereof, and the low compression ratio 690MPa grade extra thick steel plate comprises the following components by weight: 0.05%-0.14% of C, 0.12%-0.45% of Si, 0.70%-1.40% of Mn, < = 0.010% of P, < = 0.005% of S, 0.025%-0.065% of Als, < = 0.005% of N, 0.10%-0.50% of Cu, 0.50%-1.00% of Ni, 0.10%-0.40% of Cr, 0.10%-0.45% of Mo, also comprises one or more than two components selected from the following chemical components: 0.03%-0.08% of V, 0.005%-0.04% of Nb, 0.005%-0.03% of Ti, 0.0008-0.004% of B and 0.002%-0.006% of Ca, and also comprises balance of Fe and inevitable impurities, wherein the total ratio of precious and strengthening elements of Cr, Mo, Ni and Cu is less than or equal to 1.5%.

The present invention relates to methods for promoting dispersal of, or preventing formation of microbial biofilms, comprising: exposing a biofilm to an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent; treating a surface or medium susceptible to biofilm formation with an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent; incorporating an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent in a surface or medium susceptible to biofilm formation; or inducing the accumulation of one or more reactive oxygen or nitrogen species within microorganisms within said biofilm or capable of forming a biofilm. The invention also relates to methods for maintaining or enhancing or maintaining and enhancing the functioning of a biofilm, comprising exposing a biofilm to at least one nitric oxide scavenger, at least one antioxidant or at least one nitric oxide scavenger and at least one antioxidant. The invention also relates to compositions for promoting dispersal of, or preventing formation of microbial biofilms, or for maintaining or enhancing or maintaining and enhancing the functioning of microbial biofilms.

A cell population cultured ex-vivo in a culture medium under conditions permitting cells of the cell population to proliferate and, at the same time, reducing a capacity of the cells in utilizing cooper, the cells are hence expanded yet not further differentiated as compared to ex-vivo seeded cells from which the cell population developed.

The invention relates to a 2-arylaminopyridine, pyrimidine or triazine derivative and a preparation method and application thereof. The 2-arylaminopyridines, pyrimidines or triazine derivatives may act on certain mutant forms of epidermal growth factor receptors such as L858R activating mutants, delE746_A750 mutants, Exonl9 deletion activating mutants and T790M drug resistant mutants , for use in the treatment and prevention of diseases and conditions. The 2-arylaminopyridine, pyrimidine or triazine derivatives are useful for the treatment and prevention of cancer. The present invention also relates to pharmaceutical compositions comprising 2-arylaminopyridines, pyrimidines or triazine derivatives, intermediates useful in the preparation of 2-arylaminopyridines, pyrimidines or triazine derivatives, and the use of 2-arylamino Pyridine, pyrimidine or triazine derivatives in the treatment of diseases mediated by various forms of EGFR.

This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of the polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are, the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.

The invention discloses an efficient multiplication CTL preparation method killing tumors in a targeted mode. The CTL preparation method comprises the following steps: (a) removing CD4+CD25+Treg cells through immunomagnetic bead negative sorting; (b) arranging mixed cells in a serum-free medium for cultivation, and obtaining suspension cells and adherent cells; (c) adding GM-SCF and IL-4 in the adherent cells, culturing the cells for five days; in the sixth day, adding a tumour cell holoantigen, and in the seventh day, adding TNF-alpha and IL-27; (d) transferring the suspension cells to a culture flask wrapped by a CD3 monoclonal antibody and recombinant human fibronectin, adding IFN-gamma, in the second day, adding IL-2, IL-12 and the IL-27, and culturing the mixture till the eighth day to obtain CIK cells; (e) mixing the CIK cells and mature DC cells, and adding the IL-12, IL-7 and an anti-CD 28 monoclonal antibody for cultivation; in the third day, adding an anti-CTLA-4 monoclonal antibody, and then culturing the mixture for four days. According to the efficient multiplication CTL preparation method killing tumors in the targeted mode, efficiency of in-vitro CTL cell proliferation is improved, activity of killing the tumor cells in the targeted mode is improved, transformation of peripheral blood mononuclear cells to the CD4+CD25+Treg cells is inhibited.

Disclosed are methods to treat allergic conditions, including pulmonary and non-pulmonary conditions, in a subject by administering a composition that inhibits Pim kinase. Also disclosed are methods to treat allergic conditions in a subject by administering a composition that induces expression of Runx3.

A differential with a differential case, a differential gear set and a clutch pack. Apertures are formed axially through the differential case and the clutch pack to facilitate the introduction of lubricant through the differential case and into the clutch pack. An axle assembly and a method of operating an axle assembly are also provided.

Embodiments of the present invention provide methods for enhancing void-free metallic filling of narrow openings by electrochemical deposition (ECD). The methods provide enhanced replenishment of plating inhibitor at the field, while depleting the inhibitor inside narrow openings. The resulting inhibitor gradients facilitate void-free ECD filling of narrow openings with large aspect ratios. The inventive methods utilize vigorous electrolyte agitation at the field and top corners of the openings, while maintaining a relatively stagnant electrolyte inside the openings. Vigorous agitation is produced, for example, by high pressure jets flow and / or by mechanical means, such as brush (or pad, or wiper blade) wiping, or by a combination of jets and wiping brushes.

Ex vivo and in vivo methods of expanding a population of stem and / or progenitor cells, while at the same time reversibly inhibiting differentiation of the stem and / or progenitor cells by providing the stem and / or progenitor cells with an effective amount of at least one copper chelate, so as to maintain a free copper concentration available to said cells substantially unchanged, to thereby expand the population of said stem and / or progenitor cells, while at the same time reversibly inhibit differentiation of said stem and / or progenitor cells.

The invention relates to a population of progenitor cells and methods for obtaining and culturing the progenitor cells. Methods and compositions of the present invention can be useful in fields including regenerative medicine (tissue regeneration), transplantation, and cancer research.

Protoplasts which regenerate reproducibly in a short time to normal, fertile plants can be regenerated from an auxin-autotrophic genotype of Zea mays (L.). Starting from immature embryos on hormone-free media, an auxin-autotrophic, embryogenic callus is formed on the shoot basis of the seedlings, which callus retains its embryogenic potential over a substantial period of time when subcultured on hormone-free medium. In addition to fully-developed embryos, adventitious embryos are also formed under suitable culture conditions (6-9% of sucrose in the medium). When the sucrose content is reduced to 2-3% and 2,4-dichlorophenoxyacetic acid is added, soft, granular calli are formed which consist of embryogenic cell aggregates (type II callus). After subculturing the type II callus in the form of a cell suspension culture, totipotent protoplasts can be isolated. From these protoplasts, the maize plants according to the invention are regenerated.

The invention provides an undifferentiated anti-aging amplification culture medium for human umbilical cord / adipose tissue-derived stem cells. The problem in the prior art that a serum-free medium used for culturing mesenchymal stem cells is easy to differentiate and easily causes aging and apoptosis of adult stem cells is solved. The undifferentiated anti-aging amplification culture medium for human umbilical cord / adipose tissue-derived stem cells comprises cell factors, vitamins and chemical small molecules, and the culture system comprises multiple chemical small molecules and biomacromolecules and has the effects of improving physiological metabolism and proliferation and growth potential of cells, resisting oxidative stress response, scavenging free radicals, preventing DNA mutation, protecting mitochondria, reducing molecular wastes in the cells and activating longevity genes and telomerase.

The invention discloses a mixing stem cell injection and a preparation method thereof, and belongs to the field of cell preparation agents. The injection of the invention is mixture of mesenchymal stem cells from umbilical cord source and hematopoietic stem / progenitor cells from the umbilical cord blood source; the method of the mixing stem cell injection comprises the following steps: CD34+ hematopoietic stem cells are separated from the fresh umbilical cord blood and purified, and are subjected to mixed culture and amplification together with the mesenchymal stem cells from the umbilical cord source, during the amplification, the culture system is culture medium including AB umbilical cord blood plasma the volume fraction of which is 15 percent and the cell factor, 6*104 mesenchymal stem cells and CD34+ hematopoietic stem cells with the concentration of 5*104 / ml are inoculated into a culture flask and are cultured for about 10 days, and two kinds of cells are obtained at the same time, so that the mixed stem cell injection including 5*105 / ml of hematopoietic stem / progenitor cells and 2*105 / ml of mesenchymal stem cells and containing normal saline with the volume fraction of AB umbilical cord blood plasma as 15 percent is obtained.

The present invention provides a pharmaceutical composition for the prevention and treatment of a non-alcoholic fatty liver disease (NAFLD), containing an active ingredient selected from the group consisting of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof. Further, the present invention provides a method for the prevention or treatment of a non-alcoholic fatty liver disease, including administering an effective amount of an active ingredient selected from the group consisting of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof to a mammal including a human in need thereof.; Further, the present invention provides use of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof, for manufacturing a pharmaceutical composition for the prevention or treatment of a non-alcoholic fatty liver disease.

The invention discloses a serum-free medium of a stem cell, which comprises a basal medium and an additive, wherein the basal medium is DMEM / F12 (Dulbecco Modified Eagle Medium / F12); the additive comprises 2-15%(v / v) of serum replacement, 20-100ug / ml vitamin C, 0.5-10ng / ml stem cell growth factor, 5-20ng / ml human platelet-derived growth factor and 1-5mmol / ml L-glutamine. The serum-free medium of the stem cell for cell culture has the advantages of short cell cycle, strong multiplication capacity, good cell uniformity and high purity, effectively inhibits differentiation of the stem cell and adherence growth of an endothelial cell, ensures purity and dryness of the stem cell and is free from ingredients of animal origin such as fetal calf serum, and the stem cell obtained by the medium is suitable for clinical application.